TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer?

Comment

Vito Lorusso et al. J Clin Oncol. 2013.

. 2013 Jan 10;31(2):288-9.

doi: 10.1200/JCO.2012.46.2648. Epub 2012 Dec 10.

No abstract available

Comment in

Reply to V. Lorusso et al.
Gridelli C, Gallo C, Butts CA, Ciardiello F, Feld R, Perrone F. Gridelli C, et al. J Clin Oncol. 2013 Jan 10;31(2):289-9. doi: 10.1200/JCO.2012.47.0583. J Clin Oncol. 2013. PMID: 23413460 No abstract available.

First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Gridelli C, Ciardiello F, Gallo C, Feld R, Butts C, Gebbia V, Maione P, Morgillo F, Genestreti G, Favaretto A, Leighl N, Wierzbicki R, Cinieri S, Alam Y, Siena S, Tortora G, Felletti R, Riccardi F, Mancuso G, Rossi A, Cantile F, Tsao MS, Saieg M, da Cunha Santos G, Piccirillo MC, Di Maio M, Morabito A, Perrone F. Gridelli C, et al. J Clin Oncol. 2012 Aug 20;30(24):3002-11. doi: 10.1200/JCO.2011.41.2056. Epub 2012 Jul 9. J Clin Oncol. 2012. PMID: 22778317 Clinical Trial.